PACE
Prevention of Child Killers: Pneumonia and Diarrhea
22 November 2010
On November 22, 2010, key health advocates from Jordan, Syria, Lebanon, Palestine and Iraq met for a symposium to address the burden of pneumococcal and diarrheal diseases across the Eastern Mediterranean region.
The symposium convened select Ministry of Health staff from participating countries, Technical Advisory Group (TAG) members, Expanded Program on Immunisation (EPI), professional medical society leadership, pediatricians and university staff to discuss and collaborate on recommendations for expanding pneumonia and diarrheal vaccine access across the region.
Statement from Sabin Vaccine Institute on the Death of Dr. Calil K. Farhat
September 9, 2010
Sabin Executive Vice President Dr. Ciro de Quadros issued the following statement today regarding the death of Dr. Calil K. Farhat:
“The death of Calil is a great loss to the entire community of health professionals dedicated to the control of communicable diseases. He was an inspiration and a role model for all with his permanent dedication and enthusiasm. In the last few years, he was a major force with the Sabin Vaccine Institute's Pneumococcal Awareness Council of Experts (PACE) in advancing the cause for the control of pneumococcal disease,”
“Our thoughts and prayers are with his family and friends.”
Dr. Farhat died September 8, 2010 in São Paulo, Brazil. He was a titular professor in the Pediatrics Department of Federal University of São Paulo and titular professor of infectious diseases on the medicine faculty of Marilia, São Paulo, Brazil.
Sabin Vaccine Institute Applauds Meningitis Vaccine Development
July 9, 2010
Innovative Product Development Partnership Generates Meningococcal Meningitis Conjugate Vaccine
The Sabin Vaccine Institute applauds the Meningitis Vaccine Project (a partnership between the World Health Organization and PATH) and the Serum Institute of India who announced last week that a new meningococcal A conjugate vaccine, MenAfriVac™, has been approved by the WHO and will be manufactured later this year at a remarkably low-cost of $0.40 per dose.
Meningococcal meningitis, a preventable infection which is often disabling and potentially fatal, disproportionately occurs in a wide swath of Africa known as the meningitis belt —from Senegal and the Gambia in the East to Ethiopia in the West—where 430 million people are at risk of infection.
Print this page
Email this page